Identification of Caveolin-1 as a Potential Causative Factor in the Generation of Trastuzumab Resistance in Breast Cancer Cells

The oncogenic tyrosine kinase receptor ErbB2 is a prognostic factor and target for breast cancer therapeutics. In contrast with the other ErbB receptors, ErbB2 is hardly internalized by ligand induced mechanisms, indicating a prevalent surface expression. Elevated levels of ErbB2 in tumor cells are associated with its defective endocytosis and down regulation. Here we show that caveolin-1 expression in breast cancer derived SKBR-3 cells (SKBR-3/Cav-1) facilitates ligand induced ErbB2 endocytosis using an artificial peptide ligand EC-eGFP. Similarly, stimulation with humanized anti ErbB2 antibody Trastuzumab (Herceptin) was found to be internalized and co-localized with caveolin-1 in SKBR-3/Cav-1 cells. Internalized EC-eGFP and Trastuzumab in SKBR-3/Cav-1 cells were then delivered via caveolae to the caveolin-1 containing early endosomes. Consequently, attenuated Fc receptor mediated ADCC functions were observed when exposed to Trastuzumab and EC-Fc (EC-1 peptide conjugated to Fc part of human IgG). On the other hand, this caveolae dependent endocytic synergy was not observed in parental SKBR-3 cells. Therefore, caveolin-1 expression in breast cancer cells could be a predictive factor to estimate how cancer cells are likely to respond to Trastuzumab treatment.

[1]  K. Liestøl,et al.  Flotillins as regulators of ErbB2 levels in breast cancer , 2013, Oncogene.

[2]  M. Seno,et al.  Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand , 2011, Journal of cellular and molecular medicine.

[3]  T. Jovin,et al.  Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis , 2010, Proceedings of the National Academy of Sciences.

[4]  Deborah A. Brown,et al.  Caveolin-1 Induces Formation of Membrane Tubules That Sense Actomyosin Tension and Are Inhibited by Polymerase I and Transcript Release Factor/Cavin-1 , 2010, Molecular biology of the cell.

[5]  K. Gaus,et al.  Actin Dynamics Drive Membrane Reorganization and Scission in Clathrin-Independent Endocytosis , 2010, Cell.

[6]  A. Sorkin,et al.  Endocytosis and signalling: intertwining molecular networks , 2009, Nature Reviews Molecular Cell Biology.

[7]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[8]  C. Restall,et al.  Stromal cell expression of caveolin-1 predicts outcome in breast cancer. , 2009, The American journal of pathology.

[9]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[10]  Deborah A. Brown,et al.  Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells , 2008, Journal of Cell Science.

[11]  M. Peipp,et al.  Effector mechanisms of therapeutic antibodies against ErbB receptors. , 2008, Current opinion in immunology.

[12]  D. Salomon,et al.  Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2 , 2008, Cell biology international.

[13]  V. Torres,et al.  Caveolin-1: an ambiguous partner in cell signalling and cancer , 2008, Journal of cellular and molecular medicine.

[14]  Wannian Yang,et al.  Identification of the domain in ErbB2 that restricts ligand-induced degradation. , 2008, Cellular signalling.

[15]  I. Madshus,et al.  Geldanamycin-Induced Down-Regulation of ErbB2 from the Plasma Membrane Is Clathrin Dependent but Proteasomal Activity Independent , 2008, Molecular Cancer Research.

[16]  K. Roepstorff,et al.  Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer , 2008, Histochemistry and Cell Biology.

[17]  B. Kholodenko,et al.  Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses , 2007, Molecular systems biology.

[18]  S. Hubbard,et al.  Receptor tyrosine kinases: mechanisms of activation and signaling. , 2007, Current opinion in cell biology.

[19]  J. Forstová,et al.  Mouse Polyomavirus Enters Early Endosomes, Requires Their Acidic pH for Productive Infection, and Meets Transferrin Cargo in Rab11-Positive Endosomes , 2006, Journal of Virology.

[20]  F. Penault-Llorca,et al.  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? , 2006, British Journal of Cancer.

[21]  L. E. Johannessen,et al.  The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. , 2005, Molecular biology of the cell.

[22]  S. Kim,et al.  Caveolin‐1 is down‐regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast , 2005, Histopathology.

[23]  G. D'alessio,et al.  Biological properties of a human compact anti-ErbB2 antibody. , 2005, Carcinogenesis.

[24]  M. Kirkham,et al.  Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. , 2005, Biochimica et biophysica acta.

[25]  K. Sandvig,et al.  Caveolae: Stable Membrane Domains with a Potential for Internalization , 2005, Traffic.

[26]  P. Transidico,et al.  Clathrin-independent endocytosis of ubiquitinated cargos. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Sliwkowski,et al.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.

[28]  D. Weaver,et al.  Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells , 2004, International journal of cancer.

[29]  L. Pelkmans,et al.  Caveolin-Stabilized Membrane Domains as Multifunctional Transport and Sorting Devices in Endocytic Membrane Traffic , 2004, Cell.

[30]  K. Mimori,et al.  Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer , 2004, British Journal of Cancer.

[31]  Pierre Hubert,et al.  Tyrosine kinase receptors as attractive targets of cancer therapy. , 2004, Critical reviews in oncology/hematology.

[32]  M. Lisanti,et al.  The caveolin proteins , 2004, Genome Biology.

[33]  B. van Deurs,et al.  Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. , 2004, Molecular biology of the cell.

[34]  Ivan R. Nabi,et al.  Caveolae/raft-dependent endocytosis , 2003, The Journal of cell biology.

[35]  Sándor Damjanovich,et al.  Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2 , 2002, Journal of Cell Science.

[36]  Joseph Schlessinger,et al.  Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor , 2002, Cell.

[37]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[38]  Y. Yarden,et al.  Sensitivity of Mature ErbB2 to Geldanamycin Is Conferred by Its Kinase Domain and Is Mediated by the Chaperone Protein Hsp90* , 2001, The Journal of Biological Chemistry.

[39]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[40]  John M. Daly,et al.  ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.

[41]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[42]  Richard J. Lee,et al.  Reciprocal Regulation of Neu Tyrosine Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo , 1998, The Journal of Biological Chemistry.

[43]  Jan E Schnitzer,et al.  Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells , 1998, Oncogene.

[44]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[45]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[47]  M. Dowsett,et al.  The role of caveolin-1 in human breast cancer , 2011, Breast Cancer Research and Treatment.

[48]  A. Sorkin,et al.  Endocytosis and intracellular trafficking of ErbBs. , 2008, Experimental cell research.

[49]  日野 眞人.  Caveolin-1 as tumor suppressor gene in breast cancer , 2004 .

[50]  W. Fantl,et al.  Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.